News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News Zepatier to add competition to Europe’s hep C market Will company pursue same aggressive pricing strategy in Europe?
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
